Search in:

Expert Opinion on Investigational Drugs Volume 29, 2020 - Issue 5

Submit an article Journal homepage

1,632

Views

CrossRef citations to date

Altmetric

Review

New targets and therapeutics for neuroprotection, remyelination and repair in multiple sclerosis

Pablo VillosladaDepartment of Psychiatry and Behavioural Sciences & Department of Neurology and Neurological Sciences, Stanford University, California, CA, USACorrespondence[email protected]

https://orcid.org/0000-0002-8735-6119 View further author information

Lawrence SteinmanDepartment of Psychiatry and Behavioural Sciences & Department of Neurology and Neurological Sciences, Stanford University, California, CA, USA

https://orcid.org/0000-0002-2437-2250 View further author information

Pages 443-459 | Received 29 Jan 2020, Accepted 15 Apr 2020, Published online: 29 Apr 2020

Cite this article
https://doi.org/10.1080/13543784.2020.1757647
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Reprints & Permissions

Citations (28)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Articles from other publishers (28)

Jiwon Oh, Laura Airas, Daniel Harrison, Elina Järvinen, Terrie Livingston, Stefan Lanker, Rayaz A. Malik, Darin T. Okuda, Pablo Villoslada & Helga E. de Vries. (2023) Neuroimaging to monitor worsening of multiple sclerosis: advances supported by the grant for multiple sclerosis innovation. Frontiers in Neurology 14.
Crossref

Alessandra Boccaccini, Dario Cavaterra, Carmela Carnevale, Lucia Tanga, Stefano Marini, Alessio Bocedi, Pedro M. Lacal, Gianluca Manni, Grazia Graziani, Diego Sbardella & Grazia Raffaella Tundo. (2023) Novel frontiers in neuroprotective therapies in glaucoma: Molecular and clinical aspects. Molecular Aspects of Medicine 94, pages 101225.
Crossref

Ariane Mwema, Giulio G. Muccioli & Anne des Rieux. (2023) Innovative drug delivery strategies to the CNS for the treatment of multiple sclerosis. Journal of Controlled Release 364, pages 435-457.
Crossref

Manya Bhati, Swedaj Thakre & Ashish Anjankar. (2023) Nissl Granules, Axonal Regeneration, and Regenerative Therapeutics: A Comprehensive Review. Cureus.
Crossref

Michael Sy, Barbara L. Newton, Judy Pawling, Ken L. Hayama, Andres Cordon, Zhaoxia Yu, Jens Kuhle, James W. Dennis, Alexander U. Brandt & Michael Demetriou. (2023) N-acetylglucosamine inhibits inflammation and neurodegeneration markers in multiple sclerosis: a mechanistic trial. Journal of Neuroinflammation 20:1.
Crossref

Pablo Villoslada, Mar Masso, Stephane Paris, Simon Hutchings & Annelize Koch. (2023) A Phase 1 randomized study on the safety and pharmacokinetics of OCS-05, a neuroprotective disease modifying treatment for Acute Optic Neuritis and Multiple Sclerosis. Scientific Reports 13:1.
Crossref

Marianna G. Rispoli, Maria D’Apolito, Valeria Pozzilli & Valentina Tomassini. 2023. Precision Medicine in Neurodegenerative Disorders, Part II. Precision Medicine in Neurodegenerative Disorders, Part II 293 311 .

Pablo Villoslada, Keith Kennedy & Jordi Garcia-Ojalvo. 2023. Personalized Medicine Meets Artificial Intelligence. Personalized Medicine Meets Artificial Intelligence 83 95 .

Sundararajan Jayaraman & Arathi Jayaraman. (2022) Impact of histone modifier-induced protection against autoimmune encephalomyelitis on multiple sclerosis treatment. Frontiers in Neurology 13.
Crossref

Pablo Villoslada & Sara Llufriu. (2022) Preventing Neurodegeneration in Multiple Sclerosis Is Required From the Earliest Stages of the Disease. Neurology 99:15, pages 641-642.
Crossref

Doddy Denise Ojeda-Hernández, Mercedes A. Hernández-Sapiéns, Edwin E. Reza-Zaldívar, Alejandro Canales-Aguirre, Jordi A. Matías-Guiu, Jorge Matías-Guiu, Juan Carlos Mateos-Díaz, Ulises Gómez-Pinedo & Francisco Sancho-Bielsa. (2022) Exosomes and Biomaterials: In Search of a New Therapeutic Strategy for Multiple Sclerosis. Life 12:9, pages 1417.
Crossref

Vito A. G. Ricigliano, Matteo Tonietto, Mariem Hamzaoui, Émilie Poirion, Andrea Lazzarotto, Michel Bottlaender, Philippe Gervais, Elisabeth Maillart, Bruno Stankoff & Benedetta Bodini. (2022) Spontaneous remyelination in lesions protects the integrity of surrounding tissues over time in multiple sclerosis. European Journal of Neurology 29:6, pages 1719-1729.
Crossref

Stefan Bittner & Frauke Zipp. (2022) Progression in multiple sclerosis – a long-term problem. Current Opinion in Neurology 35:3, pages 293-298.
Crossref

Giuseppe Scalabrino. (2020) Epidermal Growth Factor in the CNS: A Beguiling Journey from Integrated Cell Biology to Multiple Sclerosis. An Extensive Translational Overview. Cellular and Molecular Neurobiology 42:4, pages 891-916.
Crossref

Felix Boltz, Michael Enders, Andreas Feigenspan, Philipp Kirchner, Arif Ekici & Stefanie Kuerten. (2022) Nimodipine Exerts Beneficial Effects on the Rat Oligodendrocyte Cell Line OLN-93. Brain Sciences 12:4, pages 476.
Crossref

Giuseppe Scalabrino. (2022) Newly Identified Deficiencies in the Multiple Sclerosis Central Nervous System and Their Impact on the Remyelination Failure. Biomedicines 10:4, pages 815.
Crossref

Heather Y. F. Yong & V. Wee Yong. (2021) Mechanism-based criteria to improve therapeutic outcomes in progressive multiple sclerosis. Nature Reviews Neurology 18:1, pages 40-55.
Crossref

Zhuang Song, Anithapriya Krishnan, Laura Gaetano, Nicholas J. Tustison, David Clayton, Alex de Crespigny, Thomas Bengtsson, Xiaoming Jia & Richard A.D. Carano. (2022) Deformation-based morphometry identifies deep brain structures protected by ocrelizumab. NeuroImage: Clinical 34, pages 102959.
Crossref

Kelly F. Paton, Katharina Robichon, Nikki Templeton, Lisa Denny, Afnan Al Abadey, Dan Luo, Thomas E. Prisinzano, Anne C. La Flamme & Bronwyn M. Kivell. (2021) The Salvinorin Analogue, Ethoxymethyl Ether Salvinorin B, Promotes Remyelination in Preclinical Models of Multiple Sclerosis. Frontiers in Neurology 12.
Crossref

Zhijie Zhao, Tongqi Li, Xiaohua Dong, Xiaojing Wang, Zhongxiao Zhang, Changyi Zhao, Xueran Kang, Ruizhe Zheng & Xinyuan Li. (2021) Untargeted Metabolomic Profiling of Cuprizone-Induced Demyelination in Mouse Corpus Callosum by UPLC-Orbitrap/MS Reveals Potential Metabolic Biomarkers of CNS Demyelination Disorders. Oxidative Medicine and Cellular Longevity 2021, pages 1-17.
Crossref

Christina Brown, Christina McKee, Sophia Halassy, Suleiman Kojan, Doug L. Feinstein & G. Rasul Chaudhry. (2021) Neural stem cells derived from primitive mesenchymal stem cells reversed disease symptoms and promoted neurogenesis in an experimental autoimmune encephalomyelitis mouse model of multiple sclerosis. Stem Cell Research & Therapy 12:1.
Crossref

Alexander U. Brandt, Michael Sy, Judith Bellmann-Strobl, Barbara L. Newton, Judy Pawling, Hanna G. Zimmermann, Zhaoxia Yu, Claudia Chien, Jan Dörr, Jens Th. Wuerfel, James W. Dennis, Friedemann Paul & Michael Demetriou. (2021) Association of a Marker of N -Acetylglucosamine With Progressive Multiple Sclerosis and Neurodegeneration . JAMA Neurology 78:7, pages 842.
Crossref

Pablo Villoslada, Steven L. Galetta & Ahmed Toosy. (2021) Seeing the Finish Line. Neurology 96:16, pages 731-732.
Crossref

Barbara Monti. (2021) p57kip2 nuclear export as a marker of oligodendrocytes differentiation: Towards an innovative phenotyping screening for the identification of myelin repair drugs. eBioMedicine 66, pages 103298.
Crossref

Le H. Hua. (2021) Treating MS After 50: the Role of Age in Therapeutic Decision-Making. Current Treatment Options in Neurology 23:3.
Crossref

Yaqin Sun, Jing Ji, Zheng Zha, Hui Zhao, Bing Xue, Liangyun Jin & Lei Wang. (2021) Effect and Mechanism of Catalpol on Remyelination via Regulation of the NOTCH1 Signaling Pathway. Frontiers in Pharmacology 12.
Crossref

Yael Redler & Michael Levy. (2020) Rodent Models of Optic Neuritis. Frontiers in Neurology 11.
Crossref

Sina Mojaverrostami, Parichehr Pasbakhsh, Soheila Madadi, Saeid Nekoonam, Davood Zarini, Leila Noori, Elham Shiri, Mohamad Salama, Kazem Zibara & Iraj Ragerdi Kashani. (2020) Calorie restriction promotes remyelination in a Cuprizone-Induced demyelination mouse model of multiple sclerosis. Metabolic Brain Disease 35:7, pages 1211-1224.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

New targets and therapeutics for neuroprotection, remyelination and repair in multiple sclerosis

Articles from other publishers (28)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

New targets and therapeutics for neuroprotection, remyelination and repair in multiple sclerosis

Citations (28)

Articles from other publishers (28)

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date